Citius Pharmaceuticals Inc (NASDAQ:CTXR) shares, rose in value, with the stock price down by -1.73% to the previous day’s close as strong demand from buyers drove the stock to $0.95.
Actively observing the price movement in the last trading, the stock closed the session at $0.96. The value of beta (5-year monthly) was 1.44. Referring to stock’s 52-week performance, its high was $1.71, and the low was $0.60. On the whole, CTXR has fluctuated by 29.69% over the past month.
With the market capitalization of Citius Pharmaceuticals Inc currently standing at about $150.85 million, investors are eagerly awaiting this quarter’s results, scheduled for May 10, 2024 – May 14, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.05, which is expected to increase to -$0.05 for fiscal year -$0.21 and then to about $0.12 by fiscal year 2025. Data indicates that the EPS growth is expected to be 4.50% in 2025, while the next year’s EPS growth is forecast to be 157.10%.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that CTXR’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of CTXR currently trading nearly 19.71% and 28.29% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 65.04, while the 7-day volatility ratio is showing 12.33% which for the 30-day chart, stands at 8.49%. Furthermore, Citius Pharmaceuticals Inc (CTXR)’s beta value is 1.50, and its average true range (ATR) is 0.07.
A comparison of Citius Pharmaceuticals Inc (CTXR) with its peers suggests the former has fared considerably weaker in the market. CTXR showed an intraday change of -1.73% in last session, and over the past year, it shrunk by -29.24%%.
Data on historical trading for Citius Pharmaceuticals Inc (NASDAQ:CTXR) indicates that the trading volumes over the past 10 days have averaged 0.94 million and over the past 3 months, they’ve averaged 717.55K. According to company’s latest data on outstanding shares, there are 158.86 million shares outstanding.
Nearly 7.74% of Citius Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 16.96% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 12.18 million shares as on Mar 15, 2024, resulting in a short ratio of 20.62. According to the data, the short interest in Citius Pharmaceuticals Inc (CTXR) stood at 7.66% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 11.58 million. The stock has risen by 25.34% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CTXR stock heading into the next quarter.
